Liberty Wealth Management LLC Grows Holdings in Eli Lilly and Company $LLY

Liberty Wealth Management LLC lifted its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,624 shares of the company’s stock after buying an additional 19 shares during the quarter. Liberty Wealth Management LLC’s holdings in Eli Lilly and Company were worth $1,266,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of LLY. Wealth Watch Advisors INC purchased a new position in shares of Eli Lilly and Company during the second quarter valued at approximately $387,000. AustralianSuper Pty Ltd grew its stake in Eli Lilly and Company by 60.9% in the 2nd quarter. AustralianSuper Pty Ltd now owns 19,613 shares of the company’s stock worth $15,289,000 after acquiring an additional 7,420 shares during the period. Bessemer Group Inc. raised its holdings in Eli Lilly and Company by 17.5% in the 2nd quarter. Bessemer Group Inc. now owns 332,586 shares of the company’s stock valued at $259,260,000 after acquiring an additional 49,432 shares during the last quarter. Koss Olinger Consulting LLC raised its holdings in Eli Lilly and Company by 6.0% in the 2nd quarter. Koss Olinger Consulting LLC now owns 498 shares of the company’s stock valued at $388,000 after acquiring an additional 28 shares during the last quarter. Finally, Schmidt P J Investment Management Inc. lifted its stake in shares of Eli Lilly and Company by 2.5% during the 2nd quarter. Schmidt P J Investment Management Inc. now owns 19,764 shares of the company’s stock worth $15,406,000 after purchasing an additional 482 shares during the period. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on LLY shares. HSBC lifted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. BMO Capital Markets increased their price objective on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Deutsche Bank Aktiengesellschaft lowered their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating for the company in a report on Monday, August 11th. Finally, Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $938.61.

Insider Activity

In related news, Director Jamere Jackson acquired 200 shares of the business’s stock in a transaction on Friday, August 8th. The shares were bought at an average cost of $639.56 per share, with a total value of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This trade represents a 2.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of Eli Lilly and Company stock in a transaction on Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the purchase, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. This represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought 4,514 shares of company stock worth $2,894,841 in the last quarter. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Up 0.6%

LLY opened at $825.86 on Monday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The firm has a 50 day moving average price of $768.01 and a 200 day moving average price of $768.56. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market cap of $781.65 billion, a PE ratio of 53.98, a price-to-earnings-growth ratio of 1.23 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. During the same period in the previous year, the firm earned $3.92 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.